Acquisition Target Screening
A repeatable engine for finding deals before they’re obvious.
A structured, repeatable framework for screening pharma M&A targets — strategic fit, valuation, deal-feasibility and integration risk — operated as a live engine.
"Which companies are the most credible acquisition targets for us — and in what order?"
Target screening operates as a live system: strategic-fit shortlists refreshed quarterly, valuation models updated continuously, integration-risk scored before any approach.
Acquisition target screening should run as a live engine — not a one-off project. The teams that win deals run the engine continuously and approach inside windows.
What we’re seeing in the data.
Fit beats size
TA fit, modality fit and capability complementarity outrank target size.
Live shortlists win
Quarterly-refreshed shortlists outperform annual deep-dives.
Integration risk is real
Cultural and operational integration drives 30%+ of value realization.
Approach timing matters
Approach windows tied to readouts, financing rounds and leadership transitions.
How to think about it.
-
01
Score strategic fit
TA, modality, geography, capability complementarity.
-
02
Build live valuation
PoS-weighted asset NPV per target.
-
03
Assess deal-feasibility
Capital structure, owner readiness, financing.
-
04
Score integration risk
Cultural, operational, regulatory.
-
05
Sequence approach windows
Readouts, rounds, transitions.
What separates a good answer from a defensible one.
Debt/equity mix shapes deal feasibility.
Pre-existing licensing complicates clean acquisitions.
TA-concentration risk in major markets.
Key people retention defines value realization.
Where the signal comes from.
Common questions.
How long is a typical shortlist?
20–40 targets per BD team, refreshed quarterly.
When do you actually approach?
Tie approaches to readouts, financing rounds and leadership transitions.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist